A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies.

Trial Profile

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Nivolumab (Primary) ; NKTR 214 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PIVOT-02
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 08 Aug 2017 According to Nektar Therapeutics media release, the company will present data from this study at the European Society For Medical Oncology (ESMO) 2017 Congress.
    • 08 Aug 2017 According to a Nektar Therapeutics media release, the company began dosing patients in the expansion stage of this study.
    • 05 Jun 2017 According to a Nektar Therapeutics media release, the company is looking forward to identifying a Phase 2 dose and initiating the expansion cohorts for this trial in 8 target indications in the third quarter of 2017. As of June 1, 2017, 20 patients were enrolled in the dose-escalation phase of the ongoing study in a number of dose cohorts.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top